炎症性腸疾患市場：薬剤クラス別、適応疾患別、投与経路別、流通チャネル別、地域別

世界の炎症性腸疾患市場は、2025年には233億4,000万米ドルと推定され、2032年には320億米ドルに達すると予測され、2025～2032年にかけてCAGR4.6%で成長すると予測されています。

図.炎症性腸疾患市場シェア（%）、2025年地域別

炎症性腸疾患（IBD）は、クローン病と潰瘍性大腸炎という2つの疾患を指し、消化管内の慢性炎症を特徴とします。IBDは主に小腸と大腸を侵すが、時に消化器系の他の部位に及ぶこともあります。IBDの典型的な症状は患者によって異なるが、腹痛、下痢、嘔吐、体重減少、疲労を繰り返すことが多いです。正確な病因は未だ不明であるが、IBDは遺伝的に感受性の高い患者において、環境的誘因に対する免疫応答が不適切に制御されることにより発症すると考えられています。現在利用可能な治療法は、免疫系のさまざまなコンポーネントを標的とすることにより、寛解を誘導・維持することを目的としています。これらの治療法は治癒をもたらすものではないため、IBDは世界中で臨床的・経済的に大きな負担となっています。

市場力学

世界の炎症性腸疾患市場の開拓は、ライフスタイルの変化、環境リスクの増大、先進国の寿命延長によるクローン病や潰瘍性大腸炎の有病率の上昇が主因です。また、新規の選択療法や個別化療法の開発に焦点を当てた研究開発の増加、IBDの早期診断と管理に関する意識の高まり、主要市場における医療費の増加も市場成長の原動力となっています。しかし、厳しい医薬品開発規制やIBD診断ツールや薬剤に関連する高コストが市場成長の妨げとなる可能性があります。生物製剤、幹細胞、遺伝子治療などの研究開発が進んでいることは、利害関係者に有利な機会を提供する可能性があります。

本調査の主要特徴

• 本レポートでは、世界の炎症性腸疾患市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模（10億米ドル）と複合年間成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の発売や承認、市場動向、地域による展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 本レポートから洞察により、マーケティング担当者や企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができるようになります。
• 世界の炎症性腸疾患市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この産業の様々な利害関係者に対応しています。
• 利害関係者は、世界の炎症性腸疾患市場分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• 一貫型機会マップ（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 市場動向
• 規制シナリオ
• 買収と提携のシナリオ
• 資金調達と投資
• PEST分析
• ポーターの分析

第4章 世界の炎症性腸疾患市場-コロナウイルス（COVID-19）パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 世界の炎症性腸疾患市場、薬剤クラス別、2020～2032年（10億米ドル）

• イントロダクション
• コルチコステロイド
• アミノサリチル酸
• TNF阻害剤
• 免疫抑制剤
• 抗生物質
• その他

第6章 世界の炎症性腸疾患市場、適応疾患別、2020～2032年（10億米ドル）

• イントロダクション
• 潰瘍性大腸炎
• クローン病

第7章 世界の炎症性腸疾患市場、投与経路別、2020～2032年（10億米ドル）

• イントロダクション
• 経口
• 注射

第8章 世界の炎症性腸疾患市場、流通チャネル別、2020～2032年（10億米ドル）

• イントロダクション
• 病院薬局
• 小売薬局
• オンライン薬局

第9章 世界の炎症性腸疾患市場、地域別、2020～2032年（10億米ドル）

• イントロダクション
• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第10章 競合情勢

• 企業プロファイル
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Amgen Inc.
  • UCB SA
  • Novartis AG
  • Merck &Co., Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Gilead Sciences
  • Bausch Health Companies Inc.
  • Celltrion Healthcare Co., Ltd.
  • CELGENE CORPORATION
  • COSMO PHARMACEUTICALS
  • Innovate Biopharmaceuticals
  • Sandoz
  • Horizon Therapeutics

第11章 アナリストの推奨事項

• 隆盛と衰退
• 一貫型機会マップ

第12章 参考文献と調査手法

• 参考文献
• 調査手法

Global Inflammatory Bowel Disease Market is estimated to be valued at USD 23.34 Bn in 2025 and is expected to reach USD 32.00 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.6% from 2025 to 2032.

Figure. Inflammatory Bowel Disease Market Share (%), By Region 2025

Inflammatory bowel disease (IBD) refers to two conditions - Crohn's disease and ulcerative colitis - that are characterized by chronic inflammation within the gastrointestinal tract. IBD predominantly affects the small and large intestines but can sometimes extend throughout other areas of the digestive system. Typical symptoms of IBD vary between patients but often include recurring abdominal pain, diarrhea, vomiting, weight loss, and fatigue. While the precise etiologies remain unclear, IBD is believed to arise due to inappropriately regulated immune responses to environmental triggers in genetically susceptible individuals. Currently available treatment options aim to induce and maintain remission by targeting different components of the immune system. As these approaches are not curative, IBD poses a substantial clinical and economic burden worldwide.

Market Dynamics:

Global inflammatory bowel disease market growth is primarily driven by rising prevalence of Crohn's disease and ulcerative colitis due to lifestyle changes, growing environmental risks, and prolonged lifespan in developed nations. Increasing research activities focused on developing novel selective and personalized therapies, growing awareness about early diagnosis and management of IBD, and rising healthcare expenditure across major markets can also drive the market growth. However, stringent drug development regulations and high costs associated with IBD diagnostic tools and medications can hamper the market growth. Ongoing R&D in biologics, stem cell and gene-based therapies can offer lucrative opportunities for stakeholders.

Key Features of the Study:

• This report provides in-depth analysis of the global inflammatory bowel disease market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• Key companies covered as a part of this study include AbbVie, Janssen Biotech, Takeda Pharmaceutical, UCB, and Pfizer
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global inflammatory bowel disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inflammatory bowel disease market

Detailed Segmentation-

• By Drug Class
  • Corticosteroids
  • Aminosalicylates
  • TNF Inhibitors
  • Immunosuppressant
  • Antibiotics
  • Others
• By Disease Indication
  • Ulcerative Colitis
  • Crohn's Disease
• By Route of Administration
  • Oral
  • Injectable
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Amgen Inc.
  • UCB S.A.
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Gilead Sciences
  • Bausch Health Companies Inc.
  • Celltrion Healthcare Co., Ltd.
  • CELGENE CORPORATION
  • COSMO PHARMACEUTICALS
  • Innovate Biopharmaceuticals
  • Sandoz
  • Horizon Therapeutics

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Disease Indication
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Inflammatory Bowel Disease Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Inflammatory Bowel Disease Market, By Drug Class, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Aminosalicylates
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• TNF Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Immunosuppressant
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Antibiotics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Inflammatory Bowel Disease Market, By Disease Indication, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Ulcerative Colitis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Crohn's Disease
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Inflammatory Bowel Disease Market, By Route of Administration, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Injectable
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Inflammatory Bowel Disease Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Inflammatory Bowel Disease Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • Biogen
  • Amgen Inc.
  • UCB S.A.
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Gilead Sciences
  • Bausch Health Companies Inc.
  • Celltrion Healthcare Co., Ltd.
  • CELGENE CORPORATION
  • COSMO PHARMACEUTICALS
  • Innovate Biopharmaceuticals
  • Sandoz
  • Horizon Therapeutics

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact